β-Lapachone, an NQO1 bioactivatable drug, prevents lung tumorigenesis in mice

In conclusion, our study suggests that long-term consumption of low-dose β-Lap could potentially be an effective therapeutic strategy for the prevention of lung premalignant lesions. However, further studies and clinical trials are necessary to validate our findings, determine the safety of long-term β-Lap usage in human, and promote the use of β-Lap in high-risk populations.PMID:38604545 | DOI:10.1016/j.ejphar.2024.176511

Source: European Journal of Pharmacology - April 11, 2024 Category: Drugs & Pharmacology Authors: Yaxin Chen Ruoyu Wu Xingyan Li Mengran Cao Mengdi Yang Bin Fu Chenyuan Xuan Chi Chen Yang Zhou Rong Hu Source Type: research